White House takes action against junk insurance, surprise bills

The latest stories trending on MedCity News.

Editor's Pick

Top Story Biden Administration Takes Action Against Junk Insurance, Surprise Bills The Biden Administration is proposing that short-term health plans are limited to three months, or a maximum of four months if they're extended. It comes after the Trump Administration allowed members to stay on the plans for 12 months and renew them for three years. The plans are often limited in coverage and leave consumers with high medical costs. Sponsorship Post Use a HITRUST Certified Product to Secure Your Data Presented by VenTech Solutions Protect your healthcare cloud environments for as little as $2,850 / month by using Ventech Solutions' QurCloud environmental security wrapper, including a 24X7 SOC – contact info@ventechsolutions.com. Click here for more information! Top 3 Reasons to Attend INVEST Digital Health Based upon survey feedback from last year's attendees: 1) Find Partners/Networking; 2) is a tie between, Meet Investors/Get Funding and Learn from Panel Discussions and Speakers; 3) is another tie between, Discover Startups and Learn About Innovation Opportunities. Don't miss out on your opportunity to gain all of this and more. Join Us October 26th at Pegasus Park in Dallas, TX. Hurry and Get the Lowest Ticket Price: $200 Off - Register Now!

Featured News

Enhancing Efficiency in your Practices: Unleashing the Power of Greenway Health's Optimization Services Resolve your healthcare information technology concerns by optimizing your technology, boosting workflows, improving staff productivity, and driving revenue. Swedish Startup Snags $65M for Scanning Tech Designed to Facilitate Earlier Disease Detection Neko Health recently raised €60 million (about $65.8 million) in Series A financing. The Stockholm-based startup's medical scanning technology aims to conveniently and affordably collect extensive health data to aid doctors in catching diseases early. The company's scan takes about 10 minutes and costs €250 (about $275). FDA Lifts Partial Hold on Curis Drug, Clearing Way for Phase 2 Leukemia Study A partial clinical trial hold has been lifted from cancer drug emavusertib and Curis has selected a dose to use in Phase 2 testing. The small molecule is being developed as a potential treatment for blood cancers.

Resources

Sponsored Content Introducing Payer's Place, a Video Interview Series Highlighting Healthcare Payer Executive Perspectives Presented by HLTH and MedCity News We're proud to introduce Payer's Place, a series of video interviews spotlighting perspectives from senior payer executives. The series will share insights from payers based on developments and trends they've seen in the healthcare industry and what keeps them up at night. Kicking off the series are interviews with executives from Humana and SCAN  Health Plan, which are available to view on demand in the HLTH Community. Click here to learn more!

MedCity News • PO Box 901 • New York, NY unsubscribe